Exhibit 10.8

 
AMENDMENT AGREEMENT
 
This Amendment Agreement (“Agreement”) is made and entered into as of October
10, 2017, by and among GT Biopharma Inc., a Delaware corporation (the
“Company”), and the parties identified on the signature page hereto (each a
“Note Holder” and collectively, “Note Holders”). Capitalized terms used but not
defined herein will have the meanings assigned to them in the Note Conversion
Agreements (as defined below).
 
Capitalized terms defined herein shall be incorporated in the Note Conversion
Agreements, as appropriate.
 
WHEREAS, on August 25, 2017, the Company and Note Holders identified on Schedule
A entered into Note Conversion Agreements (the “Note Conversion Agreements”);
and
 
WHEREAS, pursuant to the terms of the Note Conversion Agreements, in exchange
for the cancellation of all indebtedness of the Company, the Company issued to
the Note Holders Newly Issued Capital Stock and New Stock (as defined in the
Note Conversion Agreements; and
 
WHEREAS, pursuant to Section 8(j) of the Note Conversion Agreements, a Majority
in Interest may consent to an amendment of any provision of the Note Conversion
Agreements on behalf of the Note Holders; and
 
WHEREAS, the Company has requested the Note Holders agree to an amendment of
Section 7 of the Note Conversion Agreements.
 
NOW THEREFORE, in consideration of promises and mutual covenants contained
herein and for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereto hereby consent and agree as
follows:
 
1.           
Section 7 of the Note Conversion Agreements shall be amended as follows:
 
(a)           
the following language shall be added to the end of Section 7(a):
 
The restrictions set forth in this Section 7(a) shall terminate if the Company
issues any securities in a financing transaction for the purpose of raising
capital during any time that any New Stock is outstanding.
 
(b)           
the following language shall be added to the end of Section 7:
 
“In addition to the obligations set forth herein, beginning on October 9, 2017
until the earlier of November 30, 2017 and the end of the Restricted Period, no
shares of New Stock may be sold by a Note Holder at a sales price of less than
$7.00 per share of New Stock. During the Restricted Period, if in effect, from
and after December 1, 2017, the shares of New Stock which may be sold on a
particular trading day (the "Baseline Day") based on such Note Holder’s
Percentage (the "Allotted Shares") may be sold by such Note Holder on the
Baseline Trading Day and any one or more of the following five consecutive
trading days following the Baseline Trading Day (for example, if the Note Holder
determines that its number of Allotted Shares is 10,000 on the Baseline Trading
Day, then the Note Holder may sell the 10,000 shares over the six (6)
consecutive trading day period beginning on the Baseline Trading Day and
continuing for the following five consecutive trading days after that).”
 
 
-1-

 
 
2.           The Company will immediately notify each of the Note Holders upon
the attainment by the Company of the approval of a Majority in Interest of Note
Holders.
 
3.           
The Company represents that the foregoing amendment of Section 7 was requested
by the Company of each Note Holder and was not requested by any Note Holder.
 
4.           
Each of the Note Holders hereby represents the truth and accuracy of each Note
Holder’s representations and warranties contained in the Note Conversion
Agreement when made and also as if such representations and warranties were made
as of the date hereof.
 
5.           
Each of the Note Holders executing this Agreement represents to the Company that
it has the authority to enter into and deliver this Agreement.
 
6.           
All other terms contained in the Note Conversion Agreements remain in effect.
 
7.           Except as specifically described herein, there is no other
amendment or waiver expressed or implied.
 
8.           
Each Note Holder represents to the Company that it is making its own
determination whether it will consent to this Agreement and not as a part of a
group.
 
9.           
All notices, demands, requests, consents, approvals, and other communications
required or permitted in connection with this Agreement shall be made and given
in the same manner set forth in the Note Conversion Agreements.
 
10.           
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York without regard to conflicts of laws and principles that
would result in the application of the substantive laws of another jurisdiction.
Any action brought by either party against the other concerning the transactions
contemplated by this Agreement shall be brought only in the state courts of New
York in the federal courts located in the state of New York. Both parties and
the individuals executing this Agreement and other agreements on behalf of the
parties agree to submit to the jurisdiction of such courts and waive trial by
jury. The prevailing party (which shall be the party which receives an award
most closely resembling the remedy or action sought) shall be entitled to
recover from the other party its reasonable attorney’s fees and costs. In the
event that any provision of this Agreement or any other agreement delivered in
connection herewith is invalid or unenforceable under any applicable statute or
rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such
statute or rule of law. Any such provision which may prove invalid or
unenforceable under any law shall not affect the validity or enforceability of
any other provision of any agreement.
 
11.           This Agreement may be executed in counterparts, all of which when
taken together shall be considered one and the same Agreement and shall become
effective when the counterparts have been signed by each party and delivered to
the other party, it is being understood that all parties need not sign the same
counterpart. In the event that any signature is delivered by facsimile or PDF
transmission, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) the same with
the same force and effect as if such facsimile signature were an original
thereof.
 
-2-

 
 
IN WITNESS WHEREOF, the Company and the undersigned Note Holders have caused
this Agreement to be executed as of the date first written above.
 
GT BIOPHARMA INC.
the “Company”
 
 
 
                                                                 
By:_______________________________________
 
 
 
 
 
__________________________________________
the “Note Holder”
 
By:_______________________________________
 
 
-3-